Clorobiocin
Clorobiocin is an antibacterial agent with an IC50 of 0.21 μM against the B subunit of E. coli DNA gyrase. Clorobiocin targets the mLaC protein of Gram-negative bacteria. Clorobiocin potently inhibits bacterial DNA replication. Clorobiocin can be used in studies on Gram-negative bacterial infections, such as Acinetobacter baumannii and E. coli infections.
For research use only. We do not sell to patients.
- CAS No.: 39868-96-7
- Formula: C35H37ClN2O11
- Molecular Weight:697.13
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Combination treatment with clorobiocin (12.5 μM; overnight) and LL-37 (HY-P4744) exhibits synergistic antibacterial activity against Acinetobacter baumannii AB5075, with a fractional inhibitory concentration (FIC) value of 0.5[1].
Clorobiocin (14 μM; 24-48 h) inhibits the growth of Escherichia coli J53 in vitro with a bacteriostatic concentration of 14 μM, and the concentration required for it to inhibit bacterial growth is 67-fold higher than that required for inhibiting DNA gyrase[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 39868-96-7
-
Molecular Weight 697.13
-
Formula C35H37ClN2O11
-
SMILES
OC(C(C(OC1=O)=C2Cl)=CC=C2O[C@H](OC3(C)C)[C@@H]([C@@H]([C@H]3OC)OC(C(N4)=CC=C4C)=O)O)=C1NC(C(C=C5)=CC(C/C=C(C)\C)=C5O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huang YM, et al. Docking simulation and antibiotic discovery targeting the MlaC protein in Gram-negative bacteria. Chem Biol Drug Des. 2019;93(4):647-652. [Content Brief]
[2]. Hooper DC, et al. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother. 1982;22(4):662-671. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Clorobiocin
- 39868-96-7
- acinetobacter baumannii infection
- Escherichia coli
- Escherichia coli DNA gyrase B subunit
- Escherichia coli J53
- Acinetobacter baumannii Mla pathway
- MlaC protein
- Escherichia coli DNA gyrase
- gram-negative bacterial infection
- escherichia coli infection
- Acinetobacter baumannii
- Inhibitor
- inhibitor
- inhibit